Wednesday 23rd June 2021 - Thursday 24th June 2021
Global biosimilars market size is expected to grow from USD 35.7 billion by 2025 from USD 11.8 billion in 2020, at a CAGR of 24.7%. This industry is experiencing significant growth due to the rising incidence of chronic diseases and the increasing demand for biosimilars due to their cost-effectiveness. The growth in the market may be attributed to the cost-effectiveness of the biosimilars when compared to reference biologics coupled with the patent expiration of the many blockbuster biologic drugs. Increasing investment in the development of biosimilars will also be a key factor driving the market. According to a recent report, as many as nine drugs in the biologics category have either gone off patent or will do so by 2025. Their total revenue was $62 billion in 2018. This creates a major opportunity for their respective biosimilars. It is estimated that revenue of these biosimilars will grow by 24% annually for seven years, to $13.3 billion in 2025 in the US and Europe.
Our 15th Biosimilars Congregation 2021 will provide insight into the current state of play in the EU and stimulate debate, in a multi-stakeholder setting, on the vital role of biosimilar medicines in the sustainability of healthcare systems. Beyond a comprehensive outlook of key European market access policies, our speakers will outline the key recent developments in regulatory science and regulatory policy in the EU and other international jurisdictions. Special emphasis will be placed on strengthening the link between regulators and medical communities as an essential basis for greater understanding and acceptance of biosimilar medicines. This Biosimilars conference will focus on multiple aspects of Biosimilar product development to successfully deliver safe, Biosimilar products to the market place.